|Bid||9.10 x 800|
|Ask||9.95 x 2900|
|Day's Range||9.54 - 10.78|
|52 Week Range||1.19 - 11.57|
|Beta (5Y Monthly)||1.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.00|
Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of inflammatory lung diseases and cancer, today announced that Chimerix, Inc. (NASDAQ:CMRX), worldwide licensee of Cantex's DSTAT investigational product, yesterday reported promising results of the first cohort of patients hospitalized with COVID-19-associated Acute Lung Injury (ALI), suggesting that dociparstat sodium (DSTAT) may accelerate recovery from ALI, as well as mitigate thrombotic events in such patients. A copy of Chimerix' press release and detailed information can be found at https://ir.chimerix.com/news-releases/news-release-details/chimerix-reports-promising-topline-results-first-cohort
With me on today's call are President and Chief Executive Officer Mike Sherman, Chief Medical Officer Allen Melemed, Chief Financial and Business Officer Mike Andriole, Chief Science Officer Randall Lanier, and our newest member of the team, too, Chief Interim Technology Officer Josh Allen. Before we begin, I would like to remind you that the statements made on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors.
Chimerix Inc (NASDAQ: CMRX) reports topline results from the first cohort (n=12) of its Phase 2/3 study evaluating DSTAT in hospitalized patients with Acute Lung Injury (ALI) and COVID-19 infection. The primary endpoint of the study is survival without the need for mechanical ventilation through day 28. One patient on DSTAT was ventilated and recovered, and two patients on placebo progressed to ventilation and died. No deaths were reported in patients on the DSTAT arm. All six DSTAT patients met the clinical status assessment's improvement criteria, compared to two of the six placebo patients. No patients on DSTAT had elevated values for biomarkers related to lung inflammation and thrombotic complications. DSTAT was observed to be generally safe and well-tolerated. No patients on the DSTAT arm discontinued study treatment for adverse events compared to two patients on the placebo arm. The second cohort of 12 patients is fully enrolled, with topline data expected in the second quarter. Price Action: CMRX shares are down 1.77% at $10 in the premarket session on the last check Thursday. See more from BenzingaClick here for options trades from BenzingaCompugen's COM701 Shows Ongoing Durable Signals In Early-Stage Solid Tumor StudiesSpringWorks Therapeutics Shows Early Action In Peripheral Nerves Tumor Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.